Embodiments described herein relate to a method for preparing cultured cells, the method comprising: obtaining kidney tissue from a human subject; mechanically dissociating the tissue; subjecting the tissue to enzymatic digestion; incubating the tissue with media in a cell culture plate to form cultured cells.

The invention provides method for preparing amnion tissue grafts, as well as the grafts themselves. In specific embodiments, the tissue graft comprises a single layer of dried amnion from an umbilical cord.

The present invention relates to a decellularized nerve graft using allogeneic and heterologous nervous tissues and a method of manufacturing the same.

In the present invention, by using a low-concentration basic solution and a surfactant as a decellularization solution, cell and tissue toxicity caused by a solvent or surfactant remaining in the tissue may be minimized by minimizing the use of a basic solution and an anionic surfactant in the entire manufacturing process. In addition, a peristaltic pump may be used to maintain the tissue structure and effectively remove lipid and cells.

Preserved tissue samples contain endogenous viable cells and retain or promote biological activity after being stored at temperatures above freezing for extended periods of time (e.g., from 14 days to 3 years). The preserved tissue samples are implanted in or on a subject and, after rehydration, they retain beneficial biological activity, promote beneficial biological activity, or both. The beneficial biological activity comprises promoting one or more of tissue healing, tissue growth, and tissue generation. Methods for preparing the preserved tissue samples include contacting a recovered tissue sample with one or more protectants, followed by lyopreservation. Suitable protectants include sugars, polyphenols, carotenoids, and combinations thereof. Preferred protectants include glucose, fructose, sucrose, trehalose, dextran, EGCG, and combinations thereof. The recovered tissue sample may be any of several possible issue types. In preferred embodiments, the recovered tissue samples are selected from bone, placental, cartilage and combinations thereof.

Compositions are provided that contain biologically active components of amniotic fluid including growth factors and other proteins, carbohydrates, lipids, and metabolites. The compositions containing biologically active components of amniotic fluid can be useful for a range of therapeutic treatments including joint and soft tissue repair, regulation of skin condition, and for use in organ preservation, such as for use in organ transplant procedures. Advantages of the compositions include that they can be reproducibly produced, without the inherent variability of amniotic fluid from individual donors, and that they are free of fetal waste.

Compositions of matter comprising decellularized omentum are disclosed. The compositions may be scaffolds, hydrogels or hydrogel precursor compositions. Methods of generating the compositions are disclosed as well as uses thereof.

A barrier layer and corresponding method of making provide anti-inflammatory, non-inflammatory, and anti-adhesion functionality for a medical device implantable in a patient. The barrier layer can be combined with a medical device structure to provide anti-adhesion characteristics, in addition to improved healing, non-inflammatory, and anti-inflammatory response. The barrier layer is generally formed of a naturally occurring oil, or an oil composition formed in part of a naturally occurring oil, that is at least partially cured forming a cross-linked gel. In addition, the oil composition can include a therapeutic agent component, such as a drug or other bioactive agent.

An object of the present invention is to provide an adhesion preventing material capable of preventing adhesion safely and efficiently. The present invention provides an adhesion preventing material comprised of a cell sheet containing mesothelial cells; an adhesion preventing method and organ regeneration promoting method each using the cell sheet containing mesothelial cells.

A method of treating a spinal cord injury in a subject in need thereof is disclosed. The method comprises implanting a scaffold into the spinal cord of a subject, wherein the scaffold is seeded with oral mucosa stem cells (OMSC) and/or cells that have been ex vivo differentiated from said OMSCs, thereby treating the spinal cord injury.

Provided herein are biocompatible scaffolds engineered to convey growth stimulatory light to cells and augment their growth on the scaffolds both in vitro and in vivo. Also provide are methods of modifying biocompatible transparent waveguides to control delivery of light from the waveguide material.